Forest and Merz settle Namenda litigation

Published: 27-Jul-2010
Finance

Generic versions of drug to enter market in 2015


Pharmaceutical developer Forest Laboratories of the US and partner Merz Pharmaceuticals of Germany have signed a patent litigation settlement agreement with 10 firms that were seeking to launch generic versions of Alzheimer’s drug Namenda (memantine hydrochloride) immediate release tablets.

Under the settlement agreements, the first generic versions of memantine will enter the market on 11 January 2015. This settlement agreement is subject to review by the US Federal Trade Commission.

Forest and Merz will provide licenses to Amneal, Watson, Dr. Reddy’s, Lupin, Mylan, Orchid, Sun, Teva, Upsher-Smith, and Wockhardt.

  • Companies:
  • Forest Laboratories Inc
  • Dr Reddys Laboratories
  • Wockhardt Group
  • Merz
See more

You may also like

Finance

Acino and Merz Therapeutics sign Ukraine distribution agreement

Read more
Under the agreement, Acino will commercialise the product portfolio of Merz Therapeutics in the areas of gastroenterology, neurology and dermatology

Trending Articles

  1. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios
  2. Policy vacuum risks UK becoming a medicines supply backwater The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
  3. Lonza appoints President of Capsules and Health Ingredients Christian Seufert joins from BASF, where he has worked for the last 20 years. Most recently, he held the role of Senior VP for the Global Business Unit Pharma Solutions
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    The pros and cons of distribution agreements For life sciences companies seeking to break into overseas markets, distribution agreements are central to success
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Finance

Acino and Merz Therapeutics sign Ukraine distribution agreement

Under the agreement, Acino will commercialise the product portfolio of Merz Therapeutics in the areas of gastroenterology, neurology and dermatology
Manufacturing

Dr. Reddy’s and TR-Pharm announce strategic collaboration in Turkey

Dr. Reddy’s and TR-Pharm have entered into a strategic collaboration agreement to manufacture and commercialise a portfolio of biosimilar drugs in Turkey
Research & Development

Dr Reddy’s raises its R&D spending

Biosimilars account for around 15–20% of the overall R&D spend, representing US$45–60m
Finance

Dr Reddy’s to buy allergies and respiratory franchises in India from UCB for €118m

Strengthens its presence in dermatology, respiratory and paediatrics medicines
Finance

Operating margins expected to grow by 28% year-on-year for Indian pharma firms

Most are focusing on niche products in the US
Finance

Actavis completes US$28bn purchase of Forest Laboratories

Names new management team
Finance

Actavis to acquire Forest Laboratories for US$25bn

Creates a company with US$15bn in revenue and a growing $7bn North American speciality brand business
Subscribe now